IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

被引:0
|
作者
Sensen Zhang
Jiaren Xu
Shuang Wu
Rong Wang
Xiaoyan Qu
Wenjun Yu
Jiangyong Li
Lijuan Chen
机构
[1] The First Affiliated Hospital of Nanjing Medical University,Department of Hematology
[2] Jiangsu Province Hospital,undefined
[3] Jiangsu Province Institute of Geriatrics,undefined
来源
Medical Oncology | 2013年 / 30卷
关键词
IRF4; Myeloma; JNK pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory family, which plays an important role in many lymphoid and myeloid malignancies. In the current study, using immunohistochemical staining, we found that IRF4 only expressed in plasma cells in bone marrow biopsy samples of multiple myeloma. IRF4-positive patients displayed increased disease stage (Durie–Salmon stage, p = 0.026; and International Staging System, p = 0.005). Silencing IRF4 in myeloma cell lines could inhibit myeloma cells proliferation and induce myeloma cell apoptosis, partly by JNK/Jun pathway. These results demonstrate that IRF4 plays important roles in myelomagenesis and disease progression.
引用
收藏
相关论文
共 50 条
  • [1] IRF4 promotes cell proliferation by JNK pathway in multiple myeloma
    Zhang, Sensen
    Xu, Jiaren
    Wu, Shuang
    Wang, Rong
    Qu, Xiaoyan
    Yu, Wenjun
    Li, Jiangyong
    Chen, Lijuan
    MEDICAL ONCOLOGY, 2013, 30 (02)
  • [2] IRF4 addiction in multiple myeloma
    Arthur L. Shaffer
    N. C. Tolga Emre
    Laurence Lamy
    Vu N. Ngo
    George Wright
    Wenming Xiao
    John Powell
    Sandeep Dave
    Xin Yu
    Hong Zhao
    Yuxin Zeng
    Bangzheng Chen
    Joshua Epstein
    Louis M. Staudt
    Nature, 2008, 454 : 226 - 231
  • [3] IRF4 addiction in multiple myeloma
    Shaffer, Arthur L.
    Emre, N. C. Tolga
    Lamy, Laurence
    Ngo, Vu N.
    Wright, George
    Xiao, Wenming
    Powell, John
    Dave, Sandeep
    Yu, Xin
    Zhao, Hong
    Zeng, Yuxin
    Chen, Bangzheng
    Epstein, Joshua
    Staudt, Louis M.
    NATURE, 2008, 454 (7201) : 226 - 231
  • [4] Tuning the Innate Immune Multiple Myeloma Microenvironment By Modulating IRF4
    Vicenzi, Silvia
    Trung Tran
    Avsharian, Lara
    Hartman, Joshua
    Rapp, Anna
    Crews, Leslie
    BLOOD, 2023, 142
  • [5] Targeting SWI/SNF Extinguishes IRF4 Expression in Multiple Myeloma
    Bolomsky, Arnold
    Muppidi, Jagan
    Thomas, Craig
    Young, Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S24 - S24
  • [6] IRF4 in multiple myeloma-Biology, disease and therapeutic target
    Agnarelli, Alessandro
    Chevassut, Tim
    Mancini, Erika J.
    LEUKEMIA RESEARCH, 2018, 72 : 52 - 58
  • [7] IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
    Bolomsky, Arnold
    Ceribelli, Michele
    Scheich, Sebastian
    Rinaldi, Kristina
    Huang, Da Wei
    Chakraborty, Papiya
    Pham, Lisette
    Wright, George W.
    Hsiao, Tony
    Morris, Vivian
    Choi, Jaewoo
    Phelan, James D.
    Holewinski, Ronald J.
    Andresson, Thorkell
    Wisniewski, Jan
    Riley, Deanna
    Pittaluga, Stefania
    Hill, Elizabeth
    Thomas, Craig J.
    Muppidi, Jagan
    Young, Ryan M.
    CANCER CELL, 2024, 42 (07) : 1185 - 1201.e14
  • [8] Lenalidomide Inhibits the Multiple Myeloma Cell Survival Factor IRF4/MUM1
    Lopez-Girona, A.
    Mendy, D.
    Gaidarova, S.
    Brady, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S122 - S122
  • [9] FSCN1 promotes proliferation, invasion and glycolysis via the IRF4/AKT signaling pathway in oral squamous cell carcinoma
    Li, Liang
    Chen, Lihui
    Li, Zhangwei
    Huang, Shiqin
    Chen, Yaoyao
    Li, Zhiyong
    Chen, Wenkuan
    BMC ORAL HEALTH, 2023, 23 (01)
  • [10] FSCN1 promotes proliferation, invasion and glycolysis via the IRF4/AKT signaling pathway in oral squamous cell carcinoma
    Liang Li
    Lihui Chen
    Zhangwei Li
    Shiqin Huang
    Yaoyao Chen
    Zhiyong Li
    Wenkuan Chen
    BMC Oral Health, 23